Cellular Repair & Recovery
ARA-290
Cibinetide
ARA-290 (Cibinetide)
Research context
ARA-290 corresponds to a sequence within the helix B domain of erythropoietin, designed to engage the innate repair receptor without the erythropoietic activity of the full protein. Research examines receptor complex binding and inflammatory endpoints in tissue models.
Common assays: Innate repair receptor binding · Cytokine quantification · Erythropoietic activity comparison
Specification
| Designation | Cibinetide |
|---|---|
| Full name | ARA-290 (Cibinetide) |
| Sequence | Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| CAS number | 1208243-50-8 |
| Molecular formula | C48H82N16O18 |
| Molecular weight | 1179.27 g/mol |
| Formats | 10 mL Vial |
| Solubility | Sterile water, bacteriostatic water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
| Current lot | ARA10VAS0426 → |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Brines M, Patel NS, Villa P, et al.Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinProceedings of the National Academy of Sciences · 2008 Find on PubMed ↗
Common questions
How does ARA-290 differ from erythropoietin?
It corresponds to only the helix B region and was designed specifically to lack the erythropoietic activity of the full protein while retaining engagement with the innate repair receptor complex.
Same pathway
Related compounds
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a gastric juice sequence, studied in migration and angiogenesis models.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.
BPC-157 / TB-500
Peptide blend
A prepared blend of the two most extensively studied compounds in the repair signalling literature.